Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (scientific article (publication date: 30 November 2000))

cites work (P2860)

Q84600096	Q84600096
Q95359387	Q95359387
Q35136952	"Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients".
Q34560568	"Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate
Q53272760	2014 European Guideline on the management of sexually acquired reactive arthritis.
Q48089791	2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Q34027648	74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
Q38937842	A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business
Q82822413	A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha
Q28551075	A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients
Q88426509	A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases
Q37445355	A case of tuberculous arthritis following the use of etanercept
Q37378732	A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment.
Q36428112	A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis
Q44880279	A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis
Q93052453	A fascinating story of the discovery & development of biologicals for use in clinical medicine
Q24805534	A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg
Q35554643	A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
Q37601368	A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis.
Q36200678	A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
Q37843041	A mini-review: microRNA in arthritis
Q43885270	A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
Q64088699	A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis
Q36473075	A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Q37428436	A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
Q50460670	A novel therapeutic option in Cogan diseases? TNF-alpha blockers.
Q44080807	A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis
Q36759817	A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Q37546519	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis
Q43295674	A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).
Q46326827	A prospective study of anti-tumor necrosis factor therapy in South African rheumatoid arthritis patients.
Q35554519	A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
Q33675468	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial
Q64960426	A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Q24793114	A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626
Q38203821	A review of CT-P13: an infliximab biosimilar
Q36654727	A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response
Q34587431	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis
Q41876223	A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor alpha inhibitors
Q51261742	A tumor necrosis factor-alpha antagonist inhibits inflammatory bone resorption induced by Porphyromonas gingivalis infection in mice.
Q41925567	A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study
Q35762912	APLAR rheumatoid arthritis treatment recommendations.
Q34504843	Abatacept
Q37672814	Abatacept for the treatment of rheumatoid arthritis: A review
Q35638735	Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment
Q92857546	Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register
Q41905727	Abatacept in the treatment of rheumatoid arthritis
Q35907809	Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Q34822331	Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function
Q53632460	Absence of a clinically relevant interaction between etanercept and digoxin.
Q35099752	Accelerated development of cervical spine instabilities in rheumatoid arthritis: a prospective minimum 5-year cohort study
Q44124048	Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis
Q42121483	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
Q82323360	Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration
Q36969866	Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis
Q38082233	Active immunotherapy for chronic diseases
Q44712212	Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases
Q99547421	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review
Q54339705	Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Q57350145	Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital
Q34896439	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
Q35763157	Adalimumab in the therapy of uveitis in childhood
Q42009131	Adalimumab in the treatment of arthritis
Q33830219	Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study
Q41927602	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial
Q41937791	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
Q64379379	Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice
Q34156535	Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature
Q79832075	Administration of infliximab in general practitioners' offices is safe
Q36647850	Advanced imaging in rheumatoid arthritis: part 2: erosions.
Q51189191	Advances from clinical trials in juvenile idiopathic arthritis.
Q37102197	Advances in the diagnosis and immunotherapy for ocular inflammatory disease
Q35084877	Advances in the management of septic arthritis
Q36288599	Advances in the treatment of inflammatory arthritis
Q27691822	Advances in the treatment of rheumatoid arthritis.
Q57415315	Adverse reactions to TNF-α inhibitors in rheumatoid arthritis
Q37270827	Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor
Q41201845	Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide
Q34810094	Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis
Q36978209	Ameliorative Effects of a Polyphenolic Fraction of Cinnamomum zeylanicum L. Bark in Animal Models of Inflammation and Arthritis.
Q33676083	American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial
Q42652064	An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice
Q38854028	An update on dietary phenolic compounds in the prevention and management of rheumatoid arthritis.
Q38121621	An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis
Q37126658	An update on methotrexate pharmacogenetics in rheumatoid arthritis
Q31089069	Anakinra treatment of patients with rheumatoid arthritis
Q33776881	Analysis of Closed Claims in the Clinical Management of Rheumatoid Arthritis in Japan
Q38591275	Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product
Q42845094	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset
Q36257623	Anthocyanin Extracted from Black Soybean Seed Coats Prevents Autoimmune Arthritis by Suppressing the Development of Th17 Cells and Synthesis of Proinflammatory Cytokines by Such Cells, via Inhibition of NF-κB.
Q28553954	Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study
Q58699533	Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis
Q34983663	Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice
Q40409369	Anti-TNF agents for the treatment of spondyloarthropathies
Q37607078	Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
Q38344282	Anti-TNF in rheumatoid arthritis: an overview
Q34450313	Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases
Q83418518	Anti-TNF therapy using etanercept suppresses degenerative and inflammatory changes in skeletal muscle of older SJL/J mice
Q26997311	Anti-TNF therapy: past, present and future
Q91268857	Anti-TNF treatment negatively regulates human CD4+ T-cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype
Q36377196	Anti-TNF-alpha agents in the treatment of psoriatic arthritis
Q24801075	Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice
Q37810960	Anti-TNF-α Agents in the Treatment of Immune-Mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls
Q33792680	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.
Q40617558	Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis
Q24673716	Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety
Q35555781	Anti-tumour necrosis factor alpha therapy: can we afford it?
Q36776959	Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Q36655144	Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients
Q81430222	Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment
Q36740473	Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis
Q35967177	Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites
Q38411852	Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?
Q33944344	Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.
Q34718143	Apoptosis as a therapeutic tool in rheumatoid arthritis
Q36622653	Application of cellular gene therapy for rheumatoid arthritis
Q27692558	Applications of systems approaches in the study of rheumatic diseases
Q35554231	Appropriate and effective management of rheumatoid arthritis
Q30974442	Are "biologics" in the treatment of rheumatoid arthritis really cost effective?
Q36408155	Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities
Q46408498	Are DMARDs enough to prevent surgery in rheumatoid hands?
Q58160942	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?
Q35559514	Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys?
Q38248092	Are sample sizes of randomized clinical trials in rheumatoid arthritis too large?
Q24795018	Are synovial biopsies of diagnostic value?
Q33284147	Arthritis suppression by NADPH activation operates through an interferon-beta pathway
Q36836058	Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?
Q37856191	Assessing response and loss of response to biological therapies in IBD.
Q42161702	Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Q93053160	Assessment of latent infections in patients receiving biological therapies
Q47749650	Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis
Q35554601	Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis
Q36565844	Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis
Q36939442	Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
Q28271779	Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort
Q57306851	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis
Q51343419	Association of tumor necrosis factor-α (G-308A) genetic variant with matrix metalloproteinase-9 activity and joint destruction in early rheumatoid arthritis.
Q57647128	Association study of single nucleotide polymorphisms in pre-miRNA and rheumatoid arthritis in a Han Chinese population
Q24793159	Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols
Q82930139	Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab
Q35554200	Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers
Q41824468	Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.
Q55259964	Autoantibodies to Chemokines and Cytokines Participate in the Regulation of Cancer and Autoimmunity.
Q35555309	Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha
Q24800888	Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Q37891882	Autoimmunity and inflammation: murine models and translational studies
Q34135558	Averting inflammation by targeting the cytokine environment
Q35044577	Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety
Q88865461	B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature
Q36451422	B cell-targeted therapy for rheumatoid arthritis: an update on the evidence
Q33345109	B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?
Q35012157	Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
Q34402267	Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement
Q37347655	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
Q35031727	Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis
Q34123712	Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis
Q38993250	Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Q41702445	Biochemical and immunological characterization of a novel monoclonal antibody against mouse leukotriene B4 receptor 1.
Q27687777	Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities
Q35578072	Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis
Q41809351	Biologic agents-a panacea for inflammatory arthritis or not?
Q26852235	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Q36195284	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Q35770607	Biologic therapies: what and when?
Q36849136	Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease
Q37087438	Biologic treatments for systemic rheumatic diseases
Q35807230	Biological agents for rheumatoid arthritis: targeting both physical function and structural damage
Q38096206	Biological therapies for rheumatoid arthritis: progress to date
Q37290665	Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences
Q81339952	Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic
Q24240731	Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Q35893172	Biologics in combination with nonbiologics: efficacy and safety
Q30234528	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Q30235341	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Q24185797	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis
Q37968143	Biologics-based therapy for the treatment of rheumatoid arthritis
Q38586044	Biosimilar monoclonal antibodies: the scientific basis for extrapolation
Q38957406	Biosimilars for psoriasis: clinical studies to determine similarity.
Q57244886	Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: Comment on the concise communication by Boers
Q26777895	Bone and TNF in rheumatoid arthritis: clinical implications
Q34001621	Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention
Q34897514	Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs
Q24805600	Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis
Q39131281	Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis
Q52942737	Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control.
Q37299649	CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter
Q64054989	CD28 CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection
Q28728734	CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis
Q36327138	CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver
Q56420736	Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
Q46394309	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
Q36052535	Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk
Q35769060	Cells of the synovium in rheumatoid arthritis. Osteoclasts
Q34669386	Cellular mechanisms of chronic cell-mediated allergic conjunctivitis
Q37676988	Certolizumab pegol: a new biologic targeting rheumatoid arthritis
Q35573486	Challenges in assessing costs of rheumatoid arthritis
Q35581451	Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis
Q37895016	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
Q44253853	Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.
Q38129722	Changing incidence of orthopedic surgery in rheumatic disease: contributing factors.
Q38953729	Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab
Q37454007	Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis.
Q30540259	Chinese Herbal Formula Huo-Luo-Xiao-Ling Dan Protects against Bone Damage in Adjuvant Arthritis by Modulating the Mediators of Bone Remodeling
Q36713902	Chondroitin sulfate in the management of erosive osteoarthritis of the interphalangeal finger joints
Q36309644	Chondroprotective drugs in degenerative joint diseases
Q94545262	Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
Q24799187	Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
Q30351543	Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.
Q37443755	Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
Q34897423	Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register
Q33968506	Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study
Q34067792	Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
Q35555386	Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
Q38364465	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety
Q81091752	Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis
Q36892770	Clinical pharmacokinetics and use of infliximab
Q37120248	Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis
Q52710782	Clinical utility of eco-color-power Doppler ultrasonography and contrast enhanced magnetic resonance imaging for interpretation and quantification of joint synovitis: a review.
Q34543634	Clinically useful monoclonal antibodies in treatment
Q37668612	Clinically validated approaches to the treatment of autoimmune diseases
Q42971869	Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen.
Q34587438	Combination cytokine therapy: the next generation of rheumatoid arthritis therapy?
Q28066250	Combination therapy with biologic agents in rheumatic diseases: current and future prospects
Q37296406	Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone
Q48036355	Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
Q35190107	Combining the new biologic agents with our current psoriasis armamentarium
Q40233716	Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
Q36485893	Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
Q64247865	Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
Q36071720	Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry
Q37466558	Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Q38675968	Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controll
Q27694496	Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analy
Q35899264	Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
Q28547851	Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis
Q47731175	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results
Q43191366	Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha
Q84569891	Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy
Q41542615	Comparison of outcomes according to fixation technique following the modified Ludloff osteotomy for hallux valgus in patients with rheumatoid arthritis.
Q83048054	Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis
Q50194333	Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
Q36780936	Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?
Q35553459	Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
Q52595619	Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.
Q42279180	Computerised versus conventional methodology of radiographic joint destruction assessment in early rheumatoid arthritis
Q34413352	Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis
Q34174871	Considerations for combined immune checkpoint modulation and radiation treatment
Q36912113	Contribution of genetic studies in rodent models of autoimmune arthritis to understanding and treatment of rheumatoid arthritis
Q55079883	Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis.
Q41929910	Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
Q35907845	Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study
Q79385062	Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis
Q34248283	Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis
Q38013786	Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model
Q83001629	Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
Q33717053	Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.
Q37782588	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review
Q56904375	Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
Q37679653	Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients?
Q35552900	Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis
Q34427742	Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible
Q36371110	Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis
Q45239124	Crohn's disease over 20 years after diagnosis in a referral population
Q34479140	Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada
Q34731287	Current and future management approaches for rheumatoid arthritis
Q36655119	Current concepts and controversies in the treatment of alcoholic hepatitis
Q35214898	Current methods for the generation of human antibodies for the treatment of autoimmune diseases
Q35579503	Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
Q35594134	Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.
Q34715503	Cytokine and immunosuppressive therapies of type 1 diabetes mellitus
Q43018087	Cytokine blockers in psoriatic arthritis.
Q38656230	Cytokines and Long Noncoding RNAs
Q34830551	Cytokines and anti-cytokine biologicals in autoimmunity: present and future
Q39946607	Cytokines and cellular interactions in inflammatory synovitis
Q35552298	Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review
Q45115450	Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis.
Q33486150	DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists
Q24812386	DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
Q41552289	Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats
Q35973747	Damage control in rheumatoid arthritis. Hard-hitting, early treatment is crucial to curbing joint destruction
Q22000875	Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study
Q36032715	Decision tool to improve the quality of care in rheumatoid arthritis
Q35093040	Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis--results from a well defined population in south Sweden
Q90102556	Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders
Q34616587	Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion
Q80845146	Delayed spinal infection after laminectomy in a patient with rheumatoid arthritis interruptedly exposed to anti-tumor necrosis factor alpha agents
Q92963153	Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis
Q33645417	Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes
Q43800702	Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis F
Q24816844	Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study
Q38099211	Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics).
Q36148416	Design of effective immunotherapy for human autoimmunity
Q35638455	Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment
Q92690812	Detection of Fine Radiographic Progression in Finger Joint Space Narrowing Beyond Human Eyes: Phantom Experiment and Clinical Study with Rheumatoid Arthritis Patients
Q35907747	Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis
Q40644687	Development of a mouse-feline chimeric antibody against feline tumor necrosis factor-alpha
Q74187188	Development of anti-TNF therapy for rheumatoid arthritis
Q35759939	Development of comprehensive disease assessment in systemic vasculitis
Q28394197	Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha
Q37859679	Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease
Q34158095	Diagnosis and management of psoriatic arthritis
Q37221167	Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea
Q93154989	Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis-A Network Meta-Analysis of 36 Randomized Controlled Trials
Q38998373	Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis
Q42955923	Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
Q35677025	Discoid lupus erythematosus-like eruption induced by infliximab
Q34462435	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Q44461805	Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Q34540317	Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies
Q42677290	Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER
Q51018863	Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
Q35138666	Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients
Q33708846	Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
Q35954640	Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Q47815824	Does practice mirror the evidence base in the treatment of rheumatoid arthritis?
Q35823645	Does route of administration affect the outcome of TNF antagonist therapy?
Q33708863	Does safety make a difference in selecting the right TNF antagonist?
Q33870043	Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
Q35553970	Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
Q38182728	Dose optimization of infliximab in patients with rheumatoid arthritis
Q37119508	Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
Q77632286	Down regulation of B cells by immunization with a fusion protein of a self CD20 peptide and a foreign IgG.Fc fragment
Q37350956	Downregulation of heat shock protein 70 protects rheumatoid arthritis fibroblast-like synoviocytes from nitric oxide-induced apoptosis
Q98465635	Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
Q44654800	Drug interaction between infliximab and azathioprine in patients with Crohn's disease.
Q91934535	Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Q50083992	Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.
Q35780354	Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis
Q39881401	Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis
Q35933703	Durability and rapidity of response to anakinra in patients with rheumatoid arthritis
Q35638360	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
Q34110066	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Q35554321	Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis
Q35553379	Early rheumatoid arthritis: Toward tailor-made therapy
Q77110088	Early rheumatoid arthritis: a medical emergency?
Q36563395	Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials
Q46877741	Edaravone inhibits rheumatoid synovial cell proliferation and migration
Q24803670	Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Q42245160	Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
Q28543128	Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials
Q48250006	Effect of electro-acupuncture on tumor necrosis factor-α and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis
Q55049410	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Q45900492	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Q46394312	Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis
Q35823650	Effective use of TNF antagonists
Q90334891	Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Q37383148	Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis
Q41127155	Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan
Q35605942	Effects of PVA coated nanoparticles on human immune cells
Q26851274	Effects of anti-tumor necrosis factor α agents on bone
Q35953547	Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis
Q82906930	Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity
Q36725347	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.
Q51209335	Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice.
Q38203622	Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis
Q37616966	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Q36930704	Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
Q37172820	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
Q35638208	Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study
Q51037967	Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).
Q54571843	Efficacy and safety of reducing duration of infliximab infusion.
Q40447501	Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Q34551580	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
Q36215839	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
Q35552265	Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
Q36761766	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
Q61453693	Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis
Q36503878	Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow.
Q41827680	Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study
Q40439562	Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy
Q80426452	Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease
Q37209761	Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab
Q42603607	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
Q38993229	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
Q35026464	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
Q41911983	Efficiency of combined methotrexate/chloroquine therapy in adjuvant-induced arthritis.
Q88055955	Eleutheroside E ameliorates arthritis severity in collagen-induced arthritis mice model by suppressing inflammatory cytokine release
Q51733238	Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA.
Q37754665	Emerging biologics in the treatment of uveitis
Q34731307	Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases
Q90052768	Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies
Q26851802	Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
Q40417890	Endothelins modulate inflammatory reaction in zymosan-induced arthritis: participation of LTB4, TNF-alpha, and CXCL-1.
Q37271950	Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive
Q36145793	Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis
Q58998648	Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice
Q78431457	Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis
Q56994324	Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis
Q43955105	Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series
Q53250210	Etanercept in severe active rheumatoid arthritis: first Australian experience.
Q40578875	Etanercept in the treatment of adult patients with Still's disease
Q35551908	Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
Q34991484	Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis
Q47338654	European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Q44384544	Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly
Q39032626	Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial
Q41686103	Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Q35637221	Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Q50980583	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.
Q36823811	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis
Q38065767	Evolution of treatment for rheumatoid arthritis
Q29618020	Evolving concepts of rheumatoid arthritis
Q35632933	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis
Q28066776	Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
Q42963585	Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis
Q64934329	Expression and function of miR-155 in rat synovial fibroblast model of rheumatoid arthritis.
Q38297424	Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients
Q37359799	Expression of microRNA-146 in rheumatoid arthritis synovial tissue
Q24674079	Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years
Q90655869	Extracellular matrix turnover and inflammation in chemically-induced TMJ arthritis mouse models
Q74256124	Extraintestinal Complications of Inflammatory Bowel Disease
Q58003948	Factors Associated with Severe Skin Infections in Patients Treated with Biologic Therapies for Inflammatory Rheumatic Diseases
Q98772474	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry
Q28248826	Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation
Q35029710	Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen
Q53564506	FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.
Q90647766	Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα
Q54611416	Formation of invadopodia-like structures by synovial cells promotes cartilage breakdown in collagen-induced arthritis: involvement of the protein tyrosine kinase Src.
Q42144030	Frontiers in immunology - grand challenges
Q38659937	Functionality of Intrinsic Disorder in Tumor Necrosis Factor-α and its Receptors
Q42844958	GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice
Q46626086	GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis
Q35624547	Gene Expression Profile of T-cell Receptors in the Synovium, Peripheral Blood, and Thymus during the Initial Phase of Collagen-induced Arthritis
Q26825706	Gene expression analysis in RA: towards personalized medicine
Q34601741	Gene expression profiles: creating new perspectives in arthritis research
Q36453363	Gene expression profiling in human autoimmunity.
Q37214931	Gene polymorphisms and pharmacogenetics in rheumatoid arthritis
Q39946750	Gene therapy for rheumatoid arthritis?
Q73539170	Generation of three-dimensional pannus-like tissues in vitro from single cell suspensions of synovial fluid cells from arthritis patients
Q34731099	Genes and environment in arthritis: can RA be prevented?
Q37951648	Genetic and genomic predictors of anti-TNF response
Q35019675	Genetic clues to understanding periodic fevers, and possible therapies
Q34981859	Genetic influences on rheumatoid arthritis in African Americans
Q34886162	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci
Q34972556	Glucocorticoids and rheumatoid arthritis: back to the future?
Q28257026	Golimumab
Q34601527	Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
Q44911715	Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function fin
Q33973884	Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Q36062141	Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-Like 2 Antioxidant Pathway
Q36747670	Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases
Q56212157	Guidelines for the management of rheumatoid arthritis: 2002 Update
Q36759489	HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab
Q50157070	Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
Q38245618	Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review
Q35579507	Health economics: implications for novel antirheumatic therapies
Q30957102	Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
Q40382073	Herb Network Analysis for a Famous TCM Doctor's Prescriptions on Treatment of Rheumatoid Arthritis
Q35760039	High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis
Q42395464	High mobility group box-1 protein as a tumor necrosis factor-independent therapeutic target in rheumatoid arthritis
Q41595373	High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the
Q36494614	High-temporospatial-resolution dynamic contrast-enhanced (DCE) wrist MRI with variable-density pseudo-random circular Cartesian undersampling (CIRCUS) acquisition: evaluation of perfusion in rheumatoid arthritis patients.
Q36270103	Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis
Q46767224	Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis
Q46865512	Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis
Q37185040	Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model
Q43488190	Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy
Q46660422	How do anti-TNF therapies affect gait function in patients with rheumatoid arthritis?
Q34731292	How does infliximab work in rheumatoid arthritis?
Q34526821	How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end.
Q44083454	How should impaired morning function in rheumatoid arthritis be treated?
Q78482942	How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH
Q33614786	Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad
Q36872163	Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis
Q36292663	IKK{beta} as a target for treatment of inflammation induced bone loss
Q37983096	IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential
Q73204426	Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling
Q35638637	Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
Q47926149	Imaging in rheumatoid arthritis – why MRI and ultrasonography can no longer be ignored
Q34099969	Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?
Q37535680	Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.
Q49168236	Immunogenicity screening in protein drug development
Q79151701	Immunogenicity, efficacy and adverse events of adalimumab in RA patients
Q38114066	Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo
Q34007082	Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in adjuvant arthritis
Q37478985	Immunoregulatory role of TNFalpha in inflammatory kidney diseases
Q34360546	Immunotherapy for rheumatoid arthritis
Q35547487	Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients
Q38129036	Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
Q34109394	Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data
Q35630063	Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
Q37157473	Impact of specialty drugs on the use of other medical services.
Q37380288	Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study
Q35097253	Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life
Q90007268	In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography
Q80167144	In-office imaging in the care of patients with rheumatoid arthritis
Q51539744	Inadequate Therapy Behavior Is Associated to Disease Flares in Patients With Rheumatoid Arthritis Who Have Achieved Remission With Disease-Modifying Antirheumatic Drugs
Q51070134	Incidence and risk factors for cervical lesions in patients with rheumatoid arthritis under the current pharmacologic treatment paradigm.
Q92616949	Increased Nonexudative Age-Related Macular Degeneration Diagnosis Among Medicare Beneficiaries With Rheumatoid Arthritis
Q35638504	Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan
Q37236822	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
Q45184207	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide
Q35084908	Infection complications associated with the use of biologic agents
Q37714705	Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists
Q35581950	Infections and anti–tumor necrosis factor α therapy
Q47547409	Infectious Agents and Inflammation: The Role of Microbiota in Autoimmune Arthritis
Q36154725	Infectious complications of tumor necrosis factor-alpha antagonists
Q28083759	Inflammation induced loss of skeletal muscle
Q46055310	Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs
Q40046093	Infliximab Therapy Leading to Pulmonary Tuberculosis in a Patient With Negative Interferon γ Release Assay (IGRA)-Based QuantiFERON Gold Test
Q44016935	Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study
Q43883722	Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
Q36194610	Infliximab chimeric antitumor necrosis factor-a monoclonal antibody as potential treatment for myelodysplastic syndromes.
Q37037518	Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.
Q60049864	Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results
Q52856626	Infliximab for rheumatoid arthritis.
Q34758388	Infliximab for the treatment of rheumatoid arthritis
Q35636983	Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis
Q83191678	Infliximab in Takayasu arteritis: a safe alternative?
Q81436351	Infliximab in a child with therapy-resistant systemic vasculitis
Q35553834	Infliximab in active early rheumatoid arthritis
Q35210201	Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation
Q80541644	Infliximab in rheumatoid arthritis
Q35553741	Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations
Q35030557	Infliximab in the treatment of Crohn's disease: a user's guide for clinicians
Q37290474	Infliximab in the treatment of ankylosing spondylitis.
Q37303230	Infliximab in the treatment of rheumatoid arthritis
Q40579493	Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction
Q37577348	Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: a possible mechanism for modulation of atherogenesis.
Q24798468	Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study
Q34346418	Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months
Q35141625	Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease
Q80442663	Infliximab treatment for ocular and extraocular manifestations of Behçet's disease
Q34963107	Infliximab treatment for rheumatic disease: clinical and radiological efficacy
Q35553775	Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit
Q46812628	Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment
Q43263555	Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival
Q35201036	Infliximab treatment of rheumatoid arthritis and Crohn's disease
Q35555743	Infliximab treatment reduces complement activation in patients with rheumatoid arthritis
Q38320157	Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Q35070446	Infliximab: 12 years of experience
Q35632732	Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis
Q36286223	Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis
Q35592110	Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients
Q36573901	InforMatrix: treatment of rheumatoid arthritis using biologicals
Q44198853	Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway
Q24793412	Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid
Q35553066	Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group
Q34019267	Initiation of rheumatoid arthritis treatments and the risk of serious infections
Q90049984	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
Q36204088	Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
Q35630027	Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases
Q57226040	Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea
Q36370656	Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling
Q54320603	Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.
Q52729777	Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice.
Q35775326	Interleukin-18 as a potential target in inflammatory arthritis
Q50509527	Interleukin-1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wnt-5a/receptor tyrosine kinase-like orphan receptor 2 pathway.
Q54292098	Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.
Q34343286	Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
Q24791754	Internet hand x-rays: A comparison of joint space narrowing and erosion scores (Sharp/Genant) of plain versus digitized x-rays in rheumatoid arthritis patients
Q30804224	Interpreting radiographic data in rheumatoid arthritis
Q35141922	Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
Q37848117	Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis
Q24310184	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
Q80167229	Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?
Q54239549	Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?
Q36575283	Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
Q30675199	Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?
Q45805620	Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
Q35951845	Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
Q41948703	Is there a place for nonbiological drugs in the treatment of rheumatoid arthritis?
Q24799357	JNK1 is not essential for TNF-mediated joint disease
Q42177103	Joint blood flow is more sensitive to inflammatory arthritis than oxyhemoglobin, deoxyhemoglobin, and oxygen saturation
Q43049903	Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts
Q95269473	Joint remodeling outcome of serum levels of Dickkopf-1 (DKK1), cartilage oligomeric matrix protein (COMP), and C-telopeptide of type II collagen (CTXII) in rheumatoid arthritis
Q38181610	Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis
Q37773243	Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer
Q44241112	Knee joint destruction driven by residual local symptoms after anti-tumor necrosis factor therapy in rheumatoid arthritis
Q34989977	Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population
Q28206018	Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
Q47780673	Late infection of total knee arthroplasty inflamed by anti-TNFalpha, Infliximab therapy in rheumatoid arthritis
Q35826170	Leflunomide in active rheumatoid arthritis: a prospective study in daily practice
Q55540665	Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.
Q43061691	Leflunomide in the treatment of rheumatoid arthritis
Q35553371	Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
Q46732246	Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis
Q37663873	Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy
Q53814762	Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
Q36013828	Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score
Q33859169	Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature
Q35202521	Lithothamnion muelleri treatment ameliorates inflammatory and hypernociceptive responses in antigen-induced arthritis in mice
Q35551481	Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.
Q34562870	Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
Q38608695	Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Q73775013	Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
Q45075976	Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Q35088370	Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing
Q61908118	Low Dose Methotrexate in Inflammatory Bowel Disease: Current Status and Future Directions
Q34420269	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.
Q34654104	Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis
Q36625596	MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
Q54501729	MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
Q28084913	Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy
Q33754764	Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.
Q37439490	Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer
Q34510718	Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark?
Q35720483	Measurement of structural abnormalities in arthritis using radiographic images
Q36067667	Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors
Q37739484	Mechanistic medicine: novel strategies for clinical trials
Q41922030	Mediators of inflammation-induced bone damage in arthritis and their control by herbal products
Q37207129	Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability
Q36107389	Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis
Q90000433	Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis
Q81455223	Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis
Q37718225	Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis
Q37843718	Metastatic lymph node 51 and fibroblast-like synoviocyte hyperproliferation in rheumatoid arthritis pathogenesis
Q42734608	Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs
Q35630761	Methotrexate and psoriasis in the era of new biologic agents
Q35182959	Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?
Q38939820	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.
Q37280366	MicroRNA in autoimmunity and autoimmune diseases.
Q90469757	MicroRNA-124 inhibits TNF-α- and IL-6-induced osteoclastogenesis
Q38497399	MicroRNAs in autoimmune disease
Q35617586	MicroRNAs in systemic rheumatic diseases
Q47648942	Mitochondrial translation requires folate-dependent tRNA methylation
Q38054991	Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis
Q37210198	Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study
Q35739971	Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease
Q36099553	Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Q37401259	Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept
Q84744105	Modulation of immune and inflammatory responses on experimental arthritis following intraarticular gene transfer of tumor necrosis factor receptor-immunoglobulin Fc
Q27651515	Molecular Basis of Recognition of Human Osteopontin by 23C3, a Potential Therapeutic Antibody for Treatment of Rheumatoid Arthritis
Q24684208	Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis
Q35216972	Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis
Q40624064	Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment
Q36724093	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines
Q35026014	Monoclonal antibodies in immune and inflammatory diseases
Q36807468	Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
Q61136608	Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission
Q44078484	Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy
Q36016042	Multiplex cytokine analyses in patients with rheumatoid arthritis require use of agents blocking heterophilic antibody activity
Q45387141	Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea
Q37229440	Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention.
Q80514921	Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice
Q24812557	Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis
Q36401969	NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor
Q44378763	NF-kappaB-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis
Q57950977	Neuroendocrine Modulation Induced by Selective Blockade of TNF- in Rheumatoid Arthritis
Q52541392	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.
Q35541936	New Perspectives and Emerging Therapies for Immune-mediated Inflammatory Disorders
Q37358229	New and emerging therapies for the treatment of rheumatoid arthritis.
Q44518215	New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval
Q27023946	New insights into the impact of neuro-inflammation in rheumatoid arthritis
Q35553496	New strategies to control inflammatory synovitis: interleukin 15 and beyond
Q36088346	New therapies for rheumatoid arthritis
Q81609248	New therapies for systemic lupus erythematosus
Q36849874	New therapies for treatment of rheumatoid arthritis
Q34990105	New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies
Q34560574	New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.
Q37682875	Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity
Q34585191	Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy
Q41985051	Newly diagnosed rheumatoid arthritis
Q46565241	News on therapies for uveitis
Q56974141	No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation
Q52855355	Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?
Q36504368	Novel aspects on the contribution of T cells and dendritic cells in the pathogenesis of myositis
Q82491231	Observational Cross-Sectional Study Revealing Less Aggressive Treatment in Japanese Elderly Than Nonelderly Patients With Rheumatoid Arthritis
Q33779130	Observational studies: a valuable source for data on the true value of RA therapies
Q47917968	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience
Q35954453	Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Q36209653	Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease
Q38020460	Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
Q38020459	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
Q37519964	Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.
Q35074187	Orexigenic and anabolic agents
Q37808649	Osteoclastogenesis and arthritis
Q34826003	Osteoclasts are essential for TNF-alpha-mediated joint destruction
Q37207025	Osteoimmunology in rheumatic diseases
Q34986976	Osteoporosis in the rheumatic disease patient
Q47776871	Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice
Q35116177	Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases
Q37135491	P2 purinergic receptor modulation of cytokine production
Q47987127	P2X3 and P2X2/3 Receptors Play a Crucial Role in Articular Hyperalgesia Development Through Inflammatory Mechanisms in the Knee Joint Experimental Synovitis
Q43214803	P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis
Q41774266	PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1.
Q37720641	PLIC: protein-ligand interaction clusters
Q44472091	Paradigm of combination biologics: analytical challenges related to pharmacokinetic assays and interpretation of pharmacokinetic and immunogenicity results
Q74434021	Pathogenesis of arthritis: recent research progress
Q35772863	Pathogenic roles of B cells in human autoimmunity; insights from the clinic
Q93017920	Pathogenic stromal cells as therapeutic targets in joint inflammation
Q47896819	Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis
Q79819723	Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome
Q41828498	Patients with rheumatoid arthritis in clinical care
Q37254250	Perioperative management of medications used in the treatment of rheumatoid arthritis
Q38324573	Peripheral blood gene expression profiling in rheumatoid arthritis.
Q35151031	Perspectives on the use of gene therapy for chronic joint diseases
Q46598057	Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept
Q35637390	Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment
Q38084444	Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine
Q35976402	Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.
Q88790397	Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective
Q36192796	Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis
Q36349593	Pharmacological management of transient synovitis
Q35198225	Pharmacological treatment of established rheumatoid arthritis
Q45982095	Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
Q35741762	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
Q41917277	Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy
Q52880677	Platelet-Derived Growth Factor Receptor Activation Promotes the Prodestructive Invadosome-Forming Phenotype of Synoviocytes from Patients with Rheumatoid Arthritis.
Q80463829	Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population
Q50992326	Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy.
Q36981540	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
Q30863549	Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases
Q35902694	Practical considerations in future psoriasis therapies
Q49679337	Pre-micro RNA-499 Gene Polymorphism rs3746444 T/C is Associated with Susceptibility to Rheumatoid Arthritis in Egyptian Population.
Q37134964	Preclinical safety evaluation of recombinant adeno-associated virus 2 vector encoding human tumor necrosis factor receptor-immunoglobulin Fc fusion gene
Q36974786	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial
Q83423998	Prediction of erosion progression using ultrasound in established rheumatoid arthritis: a 2-year follow-up study
Q37372556	Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Q45939153	Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.
Q37307876	Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.
Q58204736	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study
Q34767403	Prevention or retardation of joint damage in rheumatoid arthritis: issues of definition, evaluation and interpretation of plain radiographs
Q35610243	Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Q36243974	Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects
Q38942815	Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis.
Q37563990	Prognostic factors in rheumatoid arthritis in the era of biologic agents.
Q34526927	Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification
Q38365041	Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases
Q24803611	Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies
Q34728463	Protein therapeutics: a summary and pharmacological classification
Q36040076	Psoriatic arthritis imaging: a review of scoring methods
Q36040084	Psoriatic arthritis treatment: biological response modifiers
Q35902691	Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist.
Q37221707	Psychological adjustment to chronic disease
Q80969477	Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy
Q35780344	Pursuit of optimal outcomes in rheumatoid arthritis
Q45850333	Quality of life evaluated by Short Form-8 in patients with rheumatoid arthritis who were receiving infusion of infliximab
Q35213445	Quality of life in patients with rheumatoid arthritis : which drugs might make a difference?
Q56765531	RETRACTED: Infliximab in patients with primary Sjögren's syndrome: a pilot study
Q47276152	Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNF-blocking therapies-three-year observational study
Q82673257	Radiographic measurements in the evaluation and classification of elbow joint destruction in patients with rheumatoid arthritis
Q47202397	Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies
Q35553536	Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up
Q31935385	Radiography of rheumatoid arthritis in the time of increasing drug effectiveness
Q38186577	Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review
Q35973758	Raising expectations for arthritis treatment. Biologic response modifiers are making remission possible
Q37601987	Ramsay hunt syndrome in a patient with rheumatoid arthritis after treatment with infliximab
Q37397646	Randomized controlled trial design in rheumatoid arthritis: the past decade
Q58853219	Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab
Q79991378	Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation
Q57183832	Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Q47861250	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
Q37358239	Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis
Q36051523	Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus
Q34374488	Recent advances in the treatment of the seronegative spondyloarthropathies
Q40612125	Reduction in orthopaedic surgery in patients with rheumatoid arthritis: a Norwegian register-based study
Q41762332	Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent
Q47276595	Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort
Q39726246	Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis
Q37679455	Regulatory T-cell vaccination independent of auto-antigen
Q37506211	Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study.
Q35554244	Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description
Q53540861	Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Q92798584	Remicade® (infliximab): 20 years of contributions to science and medicine
Q37691184	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
Q39389091	Reoperation rate after elbow synovectomy in rheumatoid arthritis
Q35083436	Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis
Q51417238	Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis.
Q36189976	Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort
Q29026569	Respiratory sinus arrhythmia and diseases of aging: Obesity, diabetes mellitus, and hypertension
Q49132489	Response of TNF-hyporesponsive SPRET/Ei mice in models of inflammatory disorders
Q58204694	Response to: ‘When is it not ethical to withhold treatment for rheumatoid arthritis?’ by Dr Yusuf Yazici
Q92681366	Responses to Cytokine Inhibitors Associated with Cellular Composition in Models of Immune-Mediated Inflammatory Arthritis
Q33555986	Restoring the balance: immunotherapeutic combinations for autoimmune disease
Q24800647	Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
Q47810854	Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Q83139262	Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis
Q36517701	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
Q80772239	Return of infliximab efficacy after total knee arthroplasty in a patient with rheumatoid arthritis
Q35880379	Review article: joint involvement in inflammatory bowel disease
Q35780357	Review of health economics modelling in rheumatoid arthritis
Q37118782	Review: Immune cells and mediators of inflammatory arthritis
Q36324975	Rheumatic diseases: the effects of inflammation on bone
Q57349151	Rheumatoid arthritis
Q74541001	Rheumatoid arthritis
Q38093215	Rheumatoid arthritis in the elderly and its relationship with periodontitis: a review
Q35953527	Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.
Q38357554	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Q34276012	Rheumatoid arthritis. Treatment of early disease
Q36160669	Rheumatoid arthritis: an overview of new and emerging therapies
Q41230477	Rheumatoid arthritis: biological drugs and risk of infection
Q35085103	Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases
Q35757007	Rheumatoid arthritis: refractory to infliximab, a tumor necrosis factor inhibitor
Q37120627	Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists
Q35553712	Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations
Q34098905	Rheumatology and musculoskeletal medicine
Q53413570	Rheumatology, geriatrics, and a way forward.
Q34982135	Rheumatology.
Q38182346	Risk estimation in rheumatoid arthritis: from bench to bedside
Q40621384	Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry
Q33747248	Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
Q30240183	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Q82835713	Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies
Q30240212	Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
Q33315300	Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
Q40554011	Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis
Q41605548	Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan
Q36760300	Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
Q35554865	Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
Q38234629	Rituximab and tocilizumab for the treatment of rheumatoid arthritis
Q24186568	Rituximab for rheumatoid arthritis
Q24242554	Rituximab for rheumatoid arthritis
Q36108479	Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
Q37307871	Rituximab therapy in Greek patients with rheumatoid arthritis
Q24634293	Role of PD-1 in HIV pathogenesis and as target for therapy
Q28283972	Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system
Q24675082	Role of interleukin 15 and interleukin 18 in inflammatory response
Q35553488	Role of interleukin 18 in rheumatoid arthritis.
Q33700555	Role of osteopontin in amplification and perpetuation of rheumatoid synovitis
Q37895250	Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis
Q35553478	Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF
Q44689404	STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis
Q37473648	Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy
Q35637322	Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
Q35999197	Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
Q34595156	Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept
Q89124309	Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Q42956276	Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse
Q39757212	Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects
Q37298600	Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Q24675209	Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Q35734045	Safety of tumour necrosis factor-alpha antagonists
Q33653945	Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
Q43553939	Scoring evaluation for histopathological features of synovium in patients with rheumatoid arthritis during anti-tumor necrosis factor therapy
Q35553618	Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order
Q61807055	Secretion of IL-1β From Monocytes in Gout Is Redox Independent
Q51071921	Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis.
Q51530420	Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?
Q35705082	Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
Q56452795	Serious liver disease induced by infliximab
Q59160690	Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-α therapy: a case series
Q24804764	Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept
Q82300321	Serum chemokines in patients with rheumatoid arthritis treated with etanercept
Q50918813	Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
Q45861719	Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study
Q34027422	Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
Q91740956	Sh3bp2 Gain-Of-Function Mutation Ameliorates Lupus Phenotypes in B6.MRL-Faslpr Mice
Q35915958	Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
Q36611001	Signalling platforms that modulate the inflammatory response: new targets for drug development
Q36361686	Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Q39037339	Sinusitis in patients on tumor necrosis factor alpha inhibitors.
Q38663608	Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects
Q42741713	Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study
Q36324876	Some issues with composite endpoints in clinical trials
Q41981641	Sonography and subclinical synovitis
Q44620776	Sonoporation-mediated transduction of siRNA ameliorated experimental arthritis using 3 MHz pulsed ultrasound
Q26852081	Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
Q44585210	Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis
Q38988087	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
Q44945175	Statins in rheumatoid arthritis--two birds with one stone?
Q42148555	Stem cell transplantation: limits and hopes
Q35953458	Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
Q38270024	Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.
Q81227747	Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis
Q40741708	Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice
Q34731299	Structural damage in rheumatoid arthritis as visualized through radiographs
Q42813197	Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1′ pocket and their quantitative structure–activity relationship (QSAR) study
Q44284924	Structure-activity relationships of 6-fluoroquinazolines: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation
Q35962537	Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis
Q48260743	Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept
Q64071210	Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with
Q41121882	Suppression of antibody‐mediated arthritis in mice by Fab fragments of the mediating antibodies
Q44301851	Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid
Q35579309	Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
Q42675432	Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study
Q43490943	Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine
Q34896588	Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
Q39904758	Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.
Q30822098	Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents
Q21134808	Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis
Q37587412	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis
Q35553078	Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
Q35591867	Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.
Q41837521	Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis
Q37801555	Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
Q35779864	Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
Q39255811	T Regulatory Cells in Bone Remodelling
Q36452687	T-cell activation via CD26 and caveolin-1 in rheumatoid synovium
Q35179608	T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion
Q38303870	TNF antagonists opened the way to personalized medicine in rheumatoid arthritis
Q35849817	TNF downmodulates the function of human CD4+CD25hi T-regulatory cells
Q37758202	TNF receptor 2 pathway: drug target for autoimmune diseases
Q54512993	TNF-alpha deficiency accelerates renal tubular interstitial fibrosis in the late stage of ureteral obstruction.
Q37893973	TNF-α inhibitors: are they carcinogenic?
Q36536861	TNFalpha blockade in human diseases: an overview of efficacy and safety
Q50451913	TNFalpha mechanically sensitizes masseter muscle afferent fibers of male rats.
Q35554338	TNFalpha therapy in psoriatic arthritis and psoriasis
Q34570319	TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis
Q35732863	Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention
Q40138682	Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb
Q38160905	Targeting TNF-α for the treatment of inflammatory bowel disease
Q36150612	Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis
Q99557580	Targeting co-stimulatory molecules in autoimmune disease
Q34167205	Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation
Q77838669	Targeting interleukin-1 in the treatment of rheumatoid arthritis
Q37789657	Targeting interleukin-21 in rheumatoid arthritis
Q39344907	Targeting the programmed cell death-1 pathway in rheumatoid arthritis.
Q34436456	Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases
Q45150201	Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture
Q35336802	The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug
Q34346198	The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
Q38263708	The Charcot foot as a complication of diabetic neuropathy.
Q55070918	The Effect of TNF-α on Regulatory T Cell Function in Graft-versus-Host Disease.
Q37793831	The Japanese experience with biologic therapies for rheumatoid arthritis.
Q30914777	The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
Q40868036	The association between serious infection and disease outcome in patients with rheumatoid arthritis
Q53860668	The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
Q73927216	The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care
Q37353452	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.
Q53854537	The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.
Q37681930	The degree of CD4+ T cell autoreactivity determines cellular pathways underlying inflammatory arthritis
Q34731281	The determination and measurement of functional disability in rheumatoid arthritis
Q40076942	The effect of blockade of tumor necrosis factor alpha on VLA-1+ T-cells in rheumatoid arthritis patients
Q37804483	The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
Q34626882	The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
Q37760938	The efficacy and safety of golimumab in the treatment of arthritis
Q36204163	The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
Q34401527	The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.
Q45749970	The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure
Q36401927	The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
Q45187063	The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study
Q34015801	The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation
Q81256806	The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study
Q53488703	The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis.
Q84281957	The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Q33311301	The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
Q48029200	The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
Q34984568	The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials
Q47159355	The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Q34364057	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials
Q54998113	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.
Q38108667	The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes
Q35044768	The role of innate cytokines in inflammatory response
Q34636524	The role of innate mediators in inflammatory response
Q24797889	The role of osteoprotegerin in arthritis
Q44550733	The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease
Q42624577	The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis
Q38173669	The safety of biologic therapies in RA-associated interstitial lung disease
Q35636836	The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population
Q35859217	The treatment of rheumatoid arthritis
Q35688168	The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview
Q36916918	The use of TNF-alpha blocking agents in rheumatoid arthritis: an update
Q92627208	The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Q34806563	The use of gene transfer for the protection and repair of salivary glands
Q33554356	The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project
Q37633537	Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists
Q36958902	Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
Q48825054	Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis
Q33976382	Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Q73248407	Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis
Q37552947	Therapeutic options for rheumatoid arthritis
Q40621078	Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies
Q45885673	Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse
Q35140855	Therapeutic strategies for rheumatoid arthritis
Q24806367	Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches
Q36013844	Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
Q38020364	To B or not to B the conductor of rheumatoid arthritis orchestra
Q45842857	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Q54978346	Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Q58779800	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
Q44818742	Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial
Q58204744	Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study
Q64228457	Total elbow replacement - patient selection and perspectives
Q42247134	Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets
Q33497339	Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients
Q39922923	Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.
Q41920795	Transmembrane TNF-dependent uptake of anti-TNF antibodies
Q88979580	Treadmill Running Ameliorates Destruction of Articular Cartilage and Subchondral Bone, Not Only Synovitis, in a Rheumatoid Arthritis Rat Model
Q90748781	Treadmill Running in Established Phase Arthritis Inhibits Joint Destruction in Rat Rheumatoid Arthritis Models
Q33708854	Treating psoriatic arthritis: how effective are TNF antagonists?
Q34567932	Treating rheumatoid arthritis with new disease modifying drugs
Q42775955	Treating rheumatoid arthritis with tumour necrosis factor alpha blockade
Q35556040	Treatment continuation in patients receiving biological agents or conventional DMARD therapy
Q73389017	Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease
Q57073720	Treatment of Granulomas in Patients With Ataxia Telangiectasia
Q28214774	Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
Q36663141	Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly
Q41467631	Treatment of reactive arthritis with infliximab
Q33358541	Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients
Q56060521	Treatment of rheumatoid arthritis
Q41917264	Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial
Q45180236	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report
Q34276242	Treatment of rheumatoid arthritis.
Q37607063	Treatment of rheumatoid arthritis: state of the art 2009.
Q37158791	Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Q64108857	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
Q35953268	Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
Q30885007	Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense
Q35554567	Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies
Q37129582	Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort
Q26996518	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Q36038408	Trial Watch: Monoclonal antibodies in cancer therapy
Q37302417	Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis
Q44798829	Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis
Q33328963	Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
Q43937881	Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin
Q37008829	Tumor necrosis factor as a therapeutic target of rheumatologic disease
Q59042159	Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia
Q46192977	Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials
Q34792814	Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease
Q35834811	Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective
Q41260795	Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study
Q38610068	Tumor necrosis factor-α blockade treatment decreased CD154 (CD40-ligand) expression in rheumatoid arthritis.
Q24812465	Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo
Q46031593	Tumour necrosis factor alpha activates nuclear factor kappaB signalling to reduce N-type voltage-gated Ca2+ current in postganglionic sympathetic neurons.
Q41823441	Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?
Q35174817	Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
Q35989499	Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis
Q42467603	Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
Q33614221	Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer
Q31021097	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Q36279419	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Q35086227	Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis
Q39991278	Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future
Q36165321	Unmet needs in rheumatoid arthritis
Q37851001	Unresolved issues in biologic therapy for rheumatoid arthritis
Q93053086	Update in Infectious Diseases 2019
Q37754811	Update on the use of biologics in primary systemic vasculitides
Q35638252	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Q36171750	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Q35553451	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Q34962946	Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Q35579352	Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Q35579517	Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
Q34560553	Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)
Q36955334	Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients
Q84641073	Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis
Q47447405	Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo
Q30739084	Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.
Q36059378	Using hand bone mass measurements to assess progression of rheumatoid arthritis
Q36623126	Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial
Q24673434	When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
Q37831972	When to initiate and discontinue biologic treatments for rheumatoid arthritis?
Q33566367	Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Q34731262	Why do we not have a cure for rheumatoid arthritis?
Q35579347	Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues
Q35024962	Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
Q37588725	Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?
Q44973883	Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis
Q52884662	[Anticytokine therapy].
Q84600169	[Biologic therapy and infections]
Q53855814	[Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].
Q80126732	[Biologicals: a new therapeutic approach for inflammatory diseases]
Q87792267	[Biologics]
Q78518567	[Disseminated tuberculosis in patient with rheumatoid arthritis after infliximab therapy]
Q82250522	[Effect of increasing the infliximab dose in rheumatoid arthritis]
Q79802311	[Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab]
Q84897597	[Extra-articular manifestations of rheumatoid arthritis]
Q87840407	[Inflammation and bone metabolism]
Q80365575	[Infliximab in rheumatoid arthritis-use in a third level hospital]
Q80051082	[Infliximab-induced skin reaction with visceral manifestations and high levels of anti-DNA antibodies]
Q84582827	[Local and systemic bone effects of rheumatoid arthritis]
Q84726054	[Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis]
Q80311629	[Paroxysmal nocturnal hemoglobinuria revealed by hepatic vein thrombosis (Budd-Chiari syndrome) during Infliximab therapy]
Q85010340	[Prescription of TNF-alpha inhibitors and regional differences in 2010]
Q46009980	[Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología ].
Q80220996	[Systemic candidiasis and infliximab therapy]
Q52895477	[Therapeutic strategies in rheumatoid arthritis].
Q84373485	[Treatment of patients with destructive arthritis with certolizumab pegol]
Q81696952	[Tuberculosis and infliximab treatment. National surveillance from January 1, 2000, through June 30, 2003]
Q35838512	¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis

P6179	Dimensions Publication ID	1007288012
P356	DOI	10.1056/NEJM200011303432202
P3181	OpenCitations bibliographic resource ID	2502228
P698	PubMed publication ID	11096166
P5875	ResearchGate publication ID	12232076

P50	author	Paul Emery	Q19859634
		E. William St. Clair	Q111610931
P2093	author name string	Lipsky PE
		Maini RN
		Breedveld FC
		Smolen JS
		van der Heijde DM
		Kalden JR
		Feldmann M
		Furst DE
		Weisman M
		Harriman GR
P433	issue	22
P407	language of work or name	English	Q1860
P921	main subject	rheumatoid arthritis	Q187255
		methotrexate	Q422232
P304	page(s)	1594-602
P577	publication date	2000-11-30
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
P478	volume	343

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

scientific article (publication date: 30 November 2000)

Reverse relations